Gilead targets two million remdesivir courses by year-end

By Manas Mishra (Reuters) - Gilead Sciences Inc expects supply of its potential COVID-19 drug remdesivir to exceed two million courses by year-end, the company said on Monday, more than double its previous target of 1 million. The company also said it planned to start trials of an easier-to-use inhaled version of the antiviral drug, currently administered only intravenously, by August. Remdesivir is at the forefront in the fight against the virus after the drug helped shorten hospital recovery times in a clinical trial

Reuters June 23, 2020 02:05:24 IST
Gilead targets two million remdesivir courses by year-end

Gilead targets two million remdesivir courses by yearend

By Manas Mishra

(Reuters) - Gilead Sciences Inc expects supply of its potential COVID-19 drug remdesivir to exceed two million courses by year-end, the company said on Monday, more than double its previous target of 1 million.

The company also said it planned to start trials of an easier-to-use inhaled version of the antiviral drug, currently administered only intravenously, by August.

Remdesivir is at the forefront in the fight against the virus after the drug helped shorten hospital recovery times in a clinical trial. But producing and supplying billions of doses remain major concerns as the fast-spreading respiratory illness overwhelms healthcare systems around the world.

"We will continue to collaborate globally to ensure sufficient worldwide supply," Gilead Chief Executive Officer Daniel O'Day said in a statement. (https://bit.ly/3eqpEJ9)

Two major Indian drugmakers - Hetero Labs and Cipla Ltd - on Sunday gained approval to begin selling their generic versions of remdesivir in the country. Hetero expects the treatment to be priced at 5,000 to 6,000 rupees ($66-$79) for a 100 milligram dose.

Remdesivir has not been priced yet in the United States.

Gilead's expectations of two million courses suggests sales of between $2 billion and $3 billion between 2020 and 2021 at a price of $1,000 to $2,000 per course, according to Jefferies analyst Michael Yee.

Gilead had previously said it expected to produce one million courses of remdesivir by 2020.

The company also announced plans for a "next wave of clinical trials", including studies in pregnant women.

Gilead said an inhaled formulation of the drug would be given through a nebulizer, which could potentially allow for easier use outside hospitals.

(Story corrects paragraph 5 to say Hetero, not Glenmark, expects generic version of remdesivir to be priced at 5,000 to 6,000 rupees)

(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur and Saumyadeb Chakrabarty)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

also read

France, Germany to agree to NATO role against Islamic State - sources
| Reuters
World

France, Germany to agree to NATO role against Islamic State - sources | Reuters

By Robin Emmott and John Irish | BRUSSELS/PARIS BRUSSELS/PARIS France and Germany will agree to a U.S. plan for NATO to take a bigger role in the fight against Islamic militants at a meeting with President Donald Trump on Thursday, but insist the move is purely symbolic, four senior European diplomats said.The decision to allow the North Atlantic Treaty Organization to join the coalition against Islamic State in Syria and Iraq follows weeks of pressure on the two allies, who are wary of NATO confronting Russia in Syria and of alienating Arab countries who see NATO as pushing a pro-Western agenda."NATO as an institution will join the coalition," said one senior diplomat involved in the discussions. "The question is whether this just a symbolic gesture to the United States

China's Xi says navy should become world class
| Reuters
World

China's Xi says navy should become world class | Reuters

BEIJING Chinese President Xi Jinping on Wednesday called for greater efforts to make the country's navy a world class one, strong in operations on, below and above the surface, as it steps up its ability to project power far from its shores.China's navy has taken an increasingly prominent role in recent months, with a rising star admiral taking command, its first aircraft carrier sailing around self-ruled Taiwan and a new aircraft carrier launched last month.With President Donald Trump promising a US shipbuilding spree and unnerving Beijing with his unpredictable approach on hot button issues including Taiwan and the South and East China Seas, China is pushing to narrow the gap with the U.S. Navy.Inspecting navy headquarters, Xi said the navy should "aim for the top ranks in the world", the Defence Ministry said in a statement about his visit."Building a strong and modern navy is an important mark of a top ranking global military," the ministry paraphrased Xi as saying.